What amount sold does 507 Capital Fund I, LLC report in Form D filings?

The latest linked filings report $765K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was 507 Capital Fund I, LLC's most recent SEC filing?

507 Capital Fund I, LLC's most recent Form D filing was on 2024-09-17.

How many investors does 507 Capital Fund I, LLC have?

The most recent Form D filing lists 12 investor(s).

What type of securities does 507 Capital Fund I, LLC offer?

507 Capital Fund I, LLC's SEC Form D filings indicate equity offerings.

507 Capital Fund I, LLC

CIK: 0002037771·Biotechnology·Lake Crystal, MN·Limited Liability Company·Founded 2024

Reported Sold

$765,000

Total Filings

Identified Offerings

Last Filed

Sep 17, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Sep 17, 2024Form D — New notice

Reported sold: $765,000 · Target: $10,000,000

Rule 506(b)·12 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$765,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

507 Capital LLC

Related Person

Appears on 1 filing

Zachary Alms

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 17, 2024	New	$10,000,000	$765,000	12

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Evia Bio, Inc.

Biotechnology

Offering target: $5,453,532

Filed Sep 28, 2026